Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions

European Journal of Clinical Pharmacology

Volumn 59, Issue 12, 2004, Pages 869-873

  LLerena, Adrián ^a,b   Dorado, Pedro ^a,b   Berecz, Roland ^a,c   González, Antonio P ^a   Peñas LLedó, Eva M ^a,b,d  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CYP2C9; CYP2D6; Selective serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; FLUOXETINE; NORFLUOXETINE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEADY STATE; TOBACCO DEPENDENCE;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FEMALE; FLUOXETINE; GENOTYPE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PHENOTYPE; SEROTONIN UPTAKE INHIBITORS;

EID: 1542620667     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0707-y     Document Type: Article

References (40)

1. Altamura AC, Moro AR, Percudani M (1994) Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 26:201-204
2. Preskorn SH (2000) The adverse effect profiles of the selective serotonin reuptake inhibitors: relationship to in vitro pharmacology J Pract Psych Behav Health 6:153-157
3. Claire RJ, Servis ME, Cram DL Jr (1991) Potential interaction between warfarin sodium and fluoxetine. Am J Psychiatry 148:1604
4. Woolfrey S, Gammack NS, Dewar MS, Brown PJ (1993) Fluoxetine-warfarin interaction. BMJ 307:241
5. Dent LA, Orrock MW (1997) Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 17:170-172
6. Jalil P (1992) Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 55:412-413
7. Darley J (1994) Interaction between phenytoin and fluoxetine. Seizure 3:151-152
8. Woods DJ, Coulter DM, Pillans P (1994) Interaction of phenytoin and fluoxetine. N Z Med J 107:19
9. Preskorn SH, Beber JH, Faul JC, Hirschfeld RM (1990) Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 147:532
10. Balant-Gorgia AE, Ries C, Balant LP (1996) Metabolic interaction between fluoxetine and clomipramine: a case report. Pharmacopsychiatry 29:38-41
11. Preskorn SH, Baker B (1997) Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA 277:1682
12. 450 drug interaction. Ann Pharmacother 32:761-765
13. Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, Perucca E (2002) Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 22:419-423
14. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH (2003) Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 163:59-64
15. de Abajo FJ, Rodriguez LA, Montero D (1999) Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 319:1106-1109
16. Hiemke C, Hartter S (2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85:11-28
17. Hamelin BA, Turgeon J, Vallee F, Belanger PM, Paquet F, LeBel M (1996) The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 60:512-521
18. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Wright CE, Harmatz JS, Shader RI (1997) Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology 132:402-407
19. 450 enzymes. Drug Metab Dispos 28:1187-1191
20. Lundmark J, Reis M, Bengtsson F (2001) Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit 23:139-147
21. LLerena A, Cobaleda J, Martínez C, Benítez J (1996) Interethnic differences in drug metabolism: influence of sex-related and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 21:129-138
22. 450 responsible for in vitro formation of R- and S-norfluoxetine. J Pharmacol Exp Ther 297:1044-1050
23. 4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 21:330-334
24. Skjelbo E, Brosen K (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34:256-261
25. 450 2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262-265
26. Alfaro CL, Lam YW, Simpson J, Ereshefsky L (2000) CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 40:58-66
27. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P (1995) Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 31:347-353
28. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111-122
29. 450 2C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538
30. 450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41:453-470
31. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI (1997) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 44:495-498
32. Dorado P, Berecz R, Norberto MJ, Yasar Ü, Dahl ML, LLerena A (2003) CYP2C9 genotype and diclofenac metabolism in healthy Spanish volunteers. Eur J Clin Pharmacol 59:221-225
33. 450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202
34. 450 2D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9:669-682
35. Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E (2000) Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 8:1072-1077
36. Lundqvist E, Johansson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226:327-338
37. LLerena A, Dorado P, Berecz R, Gonzalez A, Norberto MJ, de la Rubia A, Caceres M (2003) Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. J Chromatogr B 783:25-31
38. Kelly MW, Perry PJ, Holstad SG, Garvey MJ (1989) Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 11:165-170
39. Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, Brosen K (1999) The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 9:55-60
40. Jannuzzi G, Gatti G, Magni P, Spina E, Pacifici R, Zuccaro P, Torta R, Guarneri L, Perucca E (2002) Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther Drug Monit 24:616-627